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The natural history of renal allograft damage has been
characterized in serial protocol biopsies. The prevalence of
subclinical rejection (SCR) is maximal during the first months
and it is associated with the progression of interstitial
fibrosis/tubular atrophy (IF/TA) and a decreased graft
survival. IF/TA rapidly progress during the first months and
constitutes an independent predictor of graft survival. IF/TA
associated with transplant vasculopathy, SCR, or transplant
glomerulopathy implies a poorer prognosis than IF/TA
without additional lesions. These observations suggest that
protocol biopsies could be considered a surrogate of graft
survival. Preliminary data suggest that the predictive value of
protocol biopsies is not inferior to acute rejection or renal
function. Additionally, protocol biopsies have been employed
as a secondary efficacy variable in clinical trials. This strategy
has been useful to demonstrate a decrease in the progression
of IF/TA in some calcineurin-free regimens. Quantification of
renal damage is associated with graft survival suggesting
that quantitative parameters might improve the predictive
value of protocol biopsies. Validation of protocol biopsies as
a surrogate of graft survival is actively pursued, as the utility
of classical surrogates of graft outcome such as acute
rejection has become less useful because of its decreased
prevalence with actual immunosuppression.
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In the late 70s and early 80s, the interest on renal allograft
histology was mainly focused on acute rejection. In many
studies, the phenotype of infiltrating cells was characterized
as an attempt to grade the severity of rejection or to
distinguish rejection from acute cyclosporine nephrotoxicity.
The first protocol biopsy studies were performed during this
period of time, mainly to explore whether acute rejection
episodes could be predicted by histological lesions appearing
before renal function deterioration.1 It is worth to remark
that, at this time, the information on the histology of stable
grafts was really scarce. In fact, the aim of one of these
pioneering studies was just to explore whether graft histology
was normal in stable grafts.2 Many of these studies used
monoclonal antibodies to characterize interstitial infiltrating
cells, and it was observed that a proportion of stable patients
displayed different degrees of acute tubulointerstitial inflam-
mation.3,4 These findings stimulated some centers to start the
first systematic protocol biopsy programs in order to study
whether early graft lesions were associated with prognosis.
Despite the characterization of acute lesion-stimulated
protocol biopsy studies, the interest rapidly shifted to the
study of chronic lesions, as the first associations between
renal damage and outcome were observed with tubulointer-
stitial chronic but not acute damage. The introduction of
Banff criteria5–7 to evaluate indication biopsies facilitated the
use of a common classification system for renal allograft
pathology that was also applied in protocol biopsy studies.
The recent Banff meeting report has replaced the term
chronic allograft nephropathy for interstitial fibrosis/tubular
atrophy (IF/TA) in cases were no definitive underlying cause
for graft damage can be identified.8 In the present revision,
the expression IF/TA will be used throughout the text.
TEMPORAL EVOLUTION OF ACUTE AND CHRONIC RENAL
ALLOGRAFT DAMAGE
The presence of interstitial inflammation and tubulitis in
protocol biopsies obtained in stable grafts is a frequent
finding during the first months after transplantation. During
the 90s, Rush et al.9 introduced the term subclinical rejection
(SCR) to refer to stable allografts displaying an interstitial
infiltrate and tubulitis. In studies of serial protocol biopsies,
it has been demonstrated that the prevalence of SCR is
maximal during the initial 3 months, progressively decreases
until the first year, and persists in a small number of patients
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after the first year.10 Approximately 2/3 of SCR episodes are
classified as borderline changes and 1/3 as interstitial acute
rejection grade I, according to Banff criteria.10 The presence
of vascular acute rejection grade II is exceptional in protocol
biopsies.
The presence of IF/TA, referred as chronic allograft
nephropathy in the 1997 Banff criteria, rapidly progresses
during the first few months following an exponential curve
and slower thereafter. The prevalence of IF/TA in patients
treated with a calcineurin inhibitor-based regimen is
approximately 40, 60, and 90% at 3 months, 2, and 5 years,
respectively.11–13 Glomerular and vascular chronic lesions
progress at a slower rate than IF/TA.13
REPRODUCIBILITY OF HISTOLOGICAL DAMAGE IN PROTOCOL
BIOPSIES
Studies evaluating the reproducibility of renal transplant
biopsy scoring among centers showed that the interobserver
variability using the Banff 1991 schema5 was rather large,14,15
especially in the evaluation and grading of acute rejection.
Later on, a new classification system for acute rejection that
was shown to be more reproducible16 was incorporated in the
1997 Banff schema.6 In protocol biopsies, the interobserver
variability of the Banff schema has been evaluated in different
studies showing that SCR is a reproducible diagnosis
(k¼ 0.6–0.8). However, these studies demonstrated that the
reproducibility of SCR grade I was superior to borderline
changes. Rating chronic changes also gave an acceptable
interobserver agreement (k¼ 0.5–0.6 for IF/TA).17,18
SCR AND THE PROGRESSION OF IF/TA
Risk factors associated with SCR are the number of human
leukocyte antigen mismatches, degree of sensitization,
retransplantation, the presence of a previous clinical acute
rejection episode, and the immunosuppressive regimen.10,19
In this regard, it has been reported that patients treated with
tacrolimus and mycophenolate mofetil display the lowest
prevalence of SCR.10,20,21
The presence of SCR in protocol biopsies has been
consistently associated with the progression of IF/TA,
supporting that persistent interstitial inflammation is
harmful for the allograft.13,19,22 Even very-low-grade inflam-
mation has been associated with progression of chronic
tubulointerstitial damage.23 Thus, it has been proposed
that IF/TA will progress in parallel to the intensity and
duration of SCR and, consequently, a chronological sequence
of events initiated by subclinical inflammation may lead to
graft failure. This hypothesis is supported by the association
between SCR at 2-week and 10-year graft survival in a large
series of recipients of a living donor kidney.24 However,
in other studies with a shorter follow-up and a lower
statistical power, this association has not been observed.25,26
Recently, different studies have shown that the concomitant
existence of SCR, either ‘borderline changes’ or acute
rejection grade I, with IF/TA is associated with a lower graft
survival than the presence of isolated chronic lesions,22,27,28
further supporting the deleterious effect of SCR on graft
outcome.
As SCR may have a deleterious effect on long-term graft
outcome, different approaches for its prevention and
treatment have been proposed. Treatment of SCR has been
only evaluated in one prospective randomized trial. In the
treatment group, patients were biopsied at 1, 2, 3, 6, and 12
months, and SCR was treated during the first 3 months with
methylprednisolone boluses, whereas the control group was
only biopsied at 6 and 12 months. Treatment of SCR was
associated with a reduced progression of IF/TA at 6 months
and a better graft function at 2 years.29 It is important to
remark that in this study patients were treated with
cyclosporine, azathioprine, and steroids, and the prevalence
of SCR was over 30% during the initial 3 months. As
immunosuppressive schedules based on tacrolimus, myco-
phenolate mofetil, and steroids have reduced the prevalence
of SCR to very low levels, new prospective randomized
studies are needed to confirm whether this approach may still
be useful. Thus, additional trials will be necessary to clarify
whether treatment of SCR modifies renal graft outcome and
to evaluate the risk–benefit balance of protocol biopsy
programs conducted to treat SCR.30
THE SILENT PROGRESSION OF CHRONIC ALLOGRAFT LESIONS
In studies of serial protocol biopsies, chronic damage
progress, whereas serum creatinine remains stable, suggesting
that histological damage precedes renal functional deteriora-
tion.13 In a study of paired 4- and 14-month protocol
biopsies, chronic lesions significantly increased in all renal
compartments, whereas mean serum creatinine remained
unchanged.31 Even when renal function was studied with
more precise methods at 4 months in stable grafts classified
according to the presence or absence of IF/TA, glomerular
filtration rate, effective renal plasma flow, or renal functional
reserve were not different between diagnostic categories.32 In
a study of serial protocol biopsies conducted in pediatric
recipients, acute and chronic lesions were also not associated
with renal function deterioration or proteinuria.33
The progression of IF/TA has been associated with a large
number of risk factors including pre-existing donor damage,
degree of sensitization, cold ischemia time, clinical and
subclinical acute rejection, cyclosporine exposure, or renal
calcifications.11–13,34,35
CHRONIC ALLOGRAFT DAMAGE AND ITS PREDICTIVE VALUE
ON OUTCOME
In a study of 2-year protocol biopsies, Isoniemi et al.11
observed that patients displaying chronic lesions had a higher
probability for renal function deterioration and/or graft
failure, pointing out, for the first time, that lesions evaluated
by means of protocol biopsies were associated with outcome.
This study inspired the definition of the so-called ‘chronic
allograft damage index’ consisting on the sum of scores of
those lesions that correlated with serum creatinine at the time
of biopsy. Later on, Dime´ny et al.36 described an association
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between chronic histological lesions in protocol biopsies
obtained at 6 months and graft survival. This finding
introduced the notion that the information obtained from
protocol biopsies was relevant to identify patients at risk for
graft failure. Thereafter, in a 3-month protocol biopsy study
using the Banff criteria, it was again described an association
between IF/TA and graft survival. In this study, the predictive
value on outcome of IF/TA was independent from clinical
and analytical parameters such as serum creatinine, acute
rejection, or proteinuria.12 Furthermore, the chronic allograft
damage index evaluated in 1-year protocol biopsies obtained
from two pivotal mycophenolate mofetil trials was once more
an independent predictor of 3-year graft survival.37 Alto-
gether, these findings suggest that protocol biopsies contain
relevant information to predict graft outcome that is not
present in clinical or analytical data.
RECOGNITION OF HISTOLOGICAL PATTERNS THAT IMPROVE
THE PREDICTIVE VALUE OF HISTOLOGY ON OUTCOME
The presence of isolated IF/TA is only weakly associated
with graft survival, whereas there are some specific lesions
associated with IF/TA that improve its predictive value
on outcome. In a 3-month protocol biopsy study in which
biopsies were classified according to the presence or absence
of arterial intimal thickening, graft survival was signifi-
cantly reduced in patients with transplant vasculopathy.38
In another 3-month protocol biopsy study, histology was
classified according to Banff criteria as normal, IF/TA
without transplant vasculopathy, and IF/TA with transplant
vasculopathy. Ten-year graft survival was 95% in patients
with normal histology, 82% in patients with IF/TA without
transplant vasculopathy, and 41% in patients with IF/TA and
transplant vasculopathy.39 These observations support
that the recognition of histological patterns characterized
by certain groupings of lesions in different renal compart-
ments allow a more precise identification of patients at
risk for graft loss. This hypothesis was recently extended by
the description of a deleterious effect of the concomitant
association of SCR and IF/TA. In a pediatric population
biopsied at 1 year, it was noticed that survival was very poor
in patients with the simultaneous presence of SCR and
IF/TA in comparison with patients displaying IF/TA without
SCR.27 This observation was confirmed in the adult
population and extended by the observation that also
patients with SCR without IF/TA have a much better
outcome than patients with both diagnoses.22,28 It is not
clearly understood why the simultaneous presence of SCR
and IF/TA implies such a poor prognosis. It could be argued
that the inflammatory infiltrate might be more severe in
patients with SCR and IF/TA than in patients with SCR
without IF/TA. In this regard, we have observed that the
number of infiltrating B cells is increased in patients with the
simultaneous presence of SCR and IF/TA (unpublished
observation). Alternatively, we may speculate that the repair
capacity of an already damaged tissue in the presence of low-
grade inflammation may be reduced.40
Finally, in a study of 1-year protocol biopsies, it has been
observed that the simultaneous presence of IF/TA and
incipient transplant glomerulopathy implies a shorter graft
survival than the presence of IF/TA without transplant
glomerulopathy.28 This last observation raises the question
whether the recently described chronic antibody-mediated
rejection, which is characterized by specific histological
lesions, C4d deposition in peritubular capillaries, and
donor-specific antibodies,7,8 might be early diagnosed by
means of protocol biopsies. Nevertheless, information on the
utility of protocol biopsies to early detect chronic antibody-
mediated rejection is scarce. In a large multicentric study,41
the prevalence of C4d-positive protocol biopsies was 4%, and
there was no association between C4d deposition and graft
survival. Conversely, in a protocol biopsy study comparing
the progression of chronic allograft lesions in patients
receiving a living donor kidney with a positive cross-match
after plasmapheresis treatment, IF/TA progressed more
rapidly in patients with a positive C4d staining.42
Altogether, these data suggest that appropriate grouping of
histologic lesions allow to increase the predictive value of
protocol biopsy on graft survival. These observations raise
the question whether a more precise recognition of damage
patterns, for example, the coexistence of three or four of these
lesions in a biopsy may further increase the predictive value
of histological lesions.
HISTOLOGICAL LESIONS IN PROTOCOL BIOPSIES AS A
SURROGATE OF GRAFT LOSS
The gold standard outcome variable in renal transplantation
is patient and/or graft survival. The first clinical trials
performed in renal transplant patients relied on graft survival
to demonstrate differences between treatment groups.43,44
Once graft survival at 1 year was over 80%, minimum sample
size to detect a difference between groups was too large to
consider the gold standard outcome variable as a feasible
approach to differentiate between treatments. For this reason,
acute rejection was later employed as a surrogate of survival
in clinical trials until its prevalence felt below 20%.45
Nowadays, many trials are designed to test the non-
inferiority hypothesis between treatments for acute rejec-
tion.46 This situation has stimulated the search for new
surrogates of graft survival.47,48
Chronic tubulointerstitial damage, chronic vascular da-
mage, and, more recently, the presence of SCR evaluated in
protocol biopsies are independent predictors of graft survival.
These observations, confirmed at different centers, have
raised the question whether protocol biopsies could be
considered as a surrogate of graft survival, that is, a measure
that may be used instead of graft survival.49 It is important to
remark that the description of an association between
histological lesions in protocol biopsies and graft survival is
not a sufficient condition to accept histological lesions as a
surrogate of survival. There are many examples in the
literature showing that the modification by treatment of a
predictor of survival in epidemiological studies has no effect
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on survival in clinical trials. For example, although increased
levels of plasma homocysteine are associated with an
increased cardiovascular risk, supplementation with folic
acid and B vitamins had no effect on major cardiac events
despite a significant reduction of homocysteine levels.50
The validation of histological damage in protocol biopsies
as a surrogate of graft survival implies the demonstration that
changes in the prevalence of histological lesions due to
treatment modification are associated with changes in renal
allograft survival. This sequence of events has been only
described in one clinical trial evaluating early cyclosporine
withdrawal from a sirolimus- and prednisone-based regi-
men.51 The severity of chronic allograft lesions evaluated
according to the chronic allograft damage index at 3 years
was reduced and 4-year graft survival was significantly
improved in the cyclosporine withdrawal group.52 This
observation suggests that reducing the severity of chronic
lesions in protocol biopsies by treatment partly explains
improved allograft survival. However in this study, only low-
risk patients were included and the control group received
cyclosporine and sirolimus, a combination that is especially
nephrotoxic. Thus, this observation suggesting that chronic
damage in protocol biopsies constitutes a surrogate of graft
survival should be confirmed in other clinical trials evaluat-
ing different risk populations. In the other hand, co-
stimulation blockade with belatacept is also associated with
reduced severity of chronic lesions at 1 year in comparison to
a cyclosporine-based regimen. Longer follow-up of this trial
may add valuable information to further characterize the
potential value of protocol biopsies as a surrogate of graft
survival.46
ACCURACY OF PROTOCOL BIOPSIES TO PREDICT GRAFT
SURVIVAL
Despite additional information is necessary to accept that
histological damage evaluated in protocol biopsies constitu-
tes a surrogate of graft survival, it should be taken into
consideration that the interest of any surrogate depends on
its accuracy to predict the main outcome variable. Serum
creatinine has been considered a reasonable candidate to be
accepted as a surrogate of graft survival. This variable is an
independent predictor of outcome, is easy to measure and
can be obtained early after transplantation. Moreover, it has
been also shown that cyclosporine withdrawal from a
sirolimus- and prednisone-based immunosuppressive sche-
dule is associated with a lower 1-year serum creatinine and a
superior 4-year graft survival than cyclosporine mainte-
nance.51,52 Nevertheless, Kaplan et al.53 evaluated the
predictive value of serum creatinine on graft survival at 2
and 7 years and showed that it is rather low. The same was
true for estimated creatinine clearance or for the deteriora-
tion of renal function between the 6th and 12th month. As an
example, the authors transformed 1-year serum creatinine
into a binary variable using 1.8 mg/dl as the cutoff to estimate
its sensitivity and specificity to predict 7-year graft failure.
The sensitivity, that is, the proportion of patients with a
serum creatinine higher than 1.8 mg/dl who lost their graft at
7 years, was 48%. The specificity, that is, the proportion of
patients with a 1-year serum creatinine below 1.8 mg/dl who
retained their graft at 7 years, was 71%. Furthermore, they
represented this information by means of receiver operator
curves just to confirm that the predictive value of renal
function on outcome was rather low.53
The predictive value of the different histological patterns
evaluated by means of protocol biopsies on graft survival has
not been evaluated using the same approach as Kaplan et al.53
In order to obtain an approximation of the predictive value
of protocol biopsies on graft survival, we revisited a previous
publication including 435 protocol biopsies performed
during the first 6 months.22 There were 361 patients followed
for at least 7 years and 57 of them lost their graft before the
7th year. The sensitivity and specificity to predict graft loss at
7 years was calculated for different histological patterns: IF/
TA, IF/TA associated with transplant vasculopathy, or IF/TA
associated with SCR. In order to compare the predictive value
of histological lesions on 7-year graft survival with classical
clinical predictors of outcome, we also estimated accuracy,
sensitivity, and specificity for acute rejection and serum
creatinine over 1.8 mg/dl at the time of biopsy. As shown in
Table 1, the accuracy, sensitivity, and specificity of histology
was not inferior to acute rejection or serum creatinine. The
interpretation of these results is complex, as the transforma-
tion of histological patterns into a dichotomous variable is an
oversimplification. Some lesions such as IF/TA associated
with transplant vasculopathy or SCR are highly specific for
graft failure, that is, graft survival is excellent in patients
without the condition during a long period of time. In the
other hand, the sensitivity rapidly decreases, as patients not
showing the condition in the protocol biopsy will also loose
their graft because of the conditions not detected in the
protocol biopsy such as, recurrence of primary disease,
hepatitis C-related glomerulonephritis, polyoma virus
nephropathy, or treatment non-compliance. The only way
to overcome this problem is to perform iterative biopsies
to detect new patients at risk. Alternatively, validation of
composite end points considering histological and clinical/
Table 1 | Predictive value of clinical variables and different
histological patterns during the initial 6 months on 7-year
death-censored graft survival
Surrogate Category
Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
Acute rejection Yes 72 30 80
3-month SCr 41.8 mg/dl 73 58 76
Protocol
biopsy
IF/TA 67 65 67
Protocol
biopsy
IF/TA+cv-
scoreX1
81 21 92
Protocol
biopsy
IF/TA+SCR 78 31 86
cv-score, chronic vascular score according to Banff criteria; IF/TA, interstitial fibrosis/
tubular atrophy; SCr, serum creatinine; SCR, subclinical rejection.
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analytical variables together may improve the predictive value
of biopsies on outcome.54
PROTOCOL BIOPSIES AS AN EFFICACY VARIABLE IN CLINICAL
TRIALS
The lack of a trustful primary efficacy variable in clinical
trials favored the introduction of protocol biopsies as a
secondary efficacy variable in order to evaluate its potential
utility to detect differences between treatments. The first
large trial using this strategy compared cyclosporine and
tacrolimus and failed to observe a difference in the prevalence
of IF/TA between groups.55 Some years ago, the minimum
sample size to detect a difference between treatment groups
in an hypothetical trial aimed to prevent the progression of
IF/TA was estimated.39 As the incidence of IF/TA rapidly
increases during the first few months, we evaluated whether a
trial with a short-term follow-up was feasible. Thus, we
performed power calculations assuming a 6-month follow-up
and a 50% difference in the incidence of IF/TA between
treatment and control groups. For this estimation, we
considered that the mean prevalence of IF/TA in a donor
and a 6-month protocol biopsy were 16 and 38%,
respectively; and accordingly, the incidence of IF/TA was
22% (Figure 1). We estimated that minimum sample size to
detect a 50% reduction in the incidence of IF/TA from 22 to
11% was 285 patients per group (a¼ 0.05, b¼ 0.20). This
estimation was performed before the introduction of
calcineurin-free regimens, and soon we realized that our
proposal was too conservative. In a single-center study
comparing two different immunosuppressive treatments
based on cyclosporine or sirolimus associated with myco-
phenolate mofetil and prednisone, the prevalence of IF/TA at
2 years was 79% in the cyclosporine group and 33% in the
sirolimus group.56 In this study, only 24 cases per group were
necessary to demonstrate a significant difference in the
prevalence of IF/TA. Similarly, in the belatacept trial, in
which patients treated with basiliximab, mycophenolate
mofetil, and prednisone were randomized to receive an
intensive or less intensive belatacept regimen or cyclosporine,
a protocol biopsy was performed at 1 year.46 Only 50 cases
50
% of biopsies with IF/TA
40
30
20
10
0
0 3 6
∆ IF/TA = 22%
∆ IF/TA = 11%
Figure 1 | Estimation of minimum sample size in an hypothetical
clinical trial to detect a 50% reduction in the incidence of
IF/TA. For power calculation, it was assumed a 16% prevalence of
IF/TA in the preimplantation biopsy, 38% in the protocol biopsy of
the control group, and 27% in the protocol biopsy of the treatment
group. It was estimated that 285 cases per group would be necessary
to detect a difference between groups (a¼ 0.05 and b¼ 0.20).
Sample size in each group
2000
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0
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Figure 2 | Relationship between the prevalence of IF/TA in the
control and minimum sample size to detect a 50% reduction in
the prevalence of IF/TA in the study group.
Figure 3 | Quantification of cortical interstitial volume fraction in a normal and diseased renal allograft biopsies by means of a point
counting technique (silver methenamine stain, original magnification  200).
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per group were necessary to observe a significant difference in
the prevalence of IF/TA at 1 year. The prevalence of IF/TA was
29% in the intensive belatacept group, 20% in the less
intensive belatacept group, and 44% in the cyclosporine
group. However, not in all studies evaluating calcineurin-free
regimens the difference in the prevalence of chronic
tubulointerstitial damage was so evident as in the previous
mentioned trials. In patients treated with thymoglobulin,
mycophenolate mofetil, and prednisone and randomized to
receive sirolimus or tacrolimus, IF/TA at 1 year was not
different.57 These data show that in some clinical trials
evaluating calcineurin-free regimens, IF/TA has been sig-
nificantly reduced. Thus, we can foresee that if the prevalence
of IF/TA consistently falls below 20%, this variable will not be
any more useful to discriminate the effect of immunosup-
pressive treatments. This argument is based on the exponen-
tial relationship between the prevalence of the efficacy
variable and the minimum sample size as shown in Figure 2.
QUANTITATIVE EVALUATION OF HISTOLOGICAL DAMAGE
IN PROTOCOL BIOPSIES
As an attempt to improve the predictive value of protocol
biopsies on outcome, renal damage has been evaluated with
quantitative parameters based on morphometry, image
analysis, immunohistochemistry, or molecular biology tech-
niques. In protocol biopsies, the quantification of interstitial
damage by means of cortical interstitial volume fraction
with morphometry (Figure 3) or the sirius red-positive
cortical area with image analysis (Figure 4) is associated with
graft survival.58–61 Even in a clinical trial comparing
cyclosporine- versus tacrolimus-based immunosuppression,
sirius red-stained positive area was employed as an efficacy
variable.62 Additionally, the quantification of intimal arterial
volume fraction (Figure 5) and mean glomerular volume has
been also associated with graft survival.63,64 These results
suggest that quantitative parameters may provide an early
surrogate for time to graft failure. To further explore this
hypothesis, the progression of cortical interstitial volume
fraction and intimal arterial volume fraction was estimated in
serial protocol biopsies, and power calculation was per-
formed to estimate minimum sample size in an hypothetical
trial aimed to prevent the progression of interstitial or
vascular damage.65 The minimum sample size to detect a
50% reduction in the 1-year cortical interstitial volume
fraction was 50 cases per group and to detect a 50%
reduction in the 1-year intimal arterial volume fraction was
42 cases per group (a¼ 0.05, b¼ 0.20). However, these
results have to be considered with caution, as quantitative
parameters have not been properly validated as surrogates
of survival. Moreover, there is scarce information even on
intra- and interobserver variability. As an example, we
compared the interobserver variability for the estimation of
mean glomerular volume and mean intimal arterial volume
fraction in a set of protocol biopsies. As shown in Figure 6,
the agreement was better for mean glomerular volume than
for intimal thickening (unpublished observation), supporting
that the reproducibility of quantitative data depends on the
evaluated renal lesion. The low reproducibility of some
quantitative parameters may explain the paradox that, in
a
b
Figure 4 | Quantification of sirius red-positive area in a normal
and diseased renal allograft biopsy by means of image analysis
technique (original magnification  100).
Figure 5 | Quantification of intimal arterial volume fraction by means of a point counting technique in a normal artery and an artery
with transplant vasculopathy (Masson’s tricrome, original magnification  400).
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some settings, ordinal measures may be superior to
quantitative parameters to predict graft outcome. As an
example, in a study evaluating the predictive value of
histologic lesions in preimplantation biopsies, we showed
that chronic vascular lesions graded according to Banff
criteria better predicted graft outcome than quantification of
intimal thickening.66 Thus, only quantitative parameters that
are highly reproducible could offer an advantage over
classical histology.
CONCLUSION
The presence of IF/TA in protocol renal allograft biopsies is
an independent predictor of graft survival. Recently, it has
been shown that IF/TA associated with transplant vasculo-
pathy, SCR, and transplant glomerulopathy implies a poorer
outcome than IF/TA without additional lesions. These
findings raise the question whether protocol biopsies could
be employed as a surrogate of graft survival and, accordingly,
as an efficacy variable in clinical trials. Although histological
lesions predict graft survival, its accuracy has been poorly
characterized. Preliminary data suggest that its predictive
value on graft survival is at least not inferior to acute
rejection or renal function. Additionally, quantitative evalua-
tion of histological lesions has been performed as an attempt
to provide a better surrogate for time to graft failure. Both
morphometry and image analysis have been employed to
quantify interstitial fibrosis and transplant vasculopathy, but
none of these parameters has been properly validated. An
alternative strategy to increase the predictive value of
protocol biopsies on outcome is the validation of composite
end points containing histological, clinical, biological, and/or
analytical parameters.
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